

Narcolepsy and Hypersomnia: Waking Up to Orexins

Emmanuel Mignot, MD, PhD

- Ben-Joseph, R. H., Somers, V. K., Black, J., D'Agostino, R. B., Jr, Davis, M., Macfadden, W., Mues, K. E., Jackson, C., Ni, W., Cook, M. N., & White, W. B. (2024). Increased Risk of New-Onset Hypertension in Patients With Narcolepsy Initiating Sodium Oxybate: A Real-World Study. *Mayo Clinic proceedings*, 99(11), 1710–1721. <https://doi.org/10.1016/j.mayocp.2024.05.029>
- Bijlenga, D., Overeem, S., Fronczek, R., & Lammers, G. J. (2022). Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review. *Sleep*, 45(8), zsac091. <https://doi.org/10.1093/sleep/zsac091>
- Boscolo-Berto, R., Viel, G., Montagnese, S., Raduazzo, D. I., Ferrara, S. D., & Dauvilliers, Y. (2012). Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. *Sleep medicine reviews*, 16(5), 431–443. <https://doi.org/10.1016/j.smr.2011.09.001>
- Byrne, E. M., Gehrman, P. R., Trzaskowski, M., Tiemeier, H., & Pack, A. I. (2016). Genetic Correlation Analysis Suggests Association between Increased Self-Reported Sleep Duration in Adults and Schizophrenia and Type 2 Diabetes. *Sleep*, 39(10), 1853–1857. <https://doi.org/10.5665/sleep.6168>
- Dauvilliers, Y., Roth, T., Bogan, R., Thorpy, M. J., Morse, A. M., Roy, A., & Gudeman, J. (2024). Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial. *Sleep medicine*, 124, 209–216. <https://doi.org/10.1016/j.sleep.2024.09.024>
- Han, F., Lin, L., Warby, S. C., Faraco, J., Li, J., Dong, S. X., An, P., Zhao, L., Wang, L. H., Li, Q. Y., Yan, H., Gao, Z. C., Yuan, Y., Strohl, K. P., & Mignot, E. (2011). Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. *Annals of neurology*, 70(3), 410–417. <https://doi.org/10.1002/ana.22587>

Jones, S. E., Tyrrell, J., Wood, A. R., Beaumont, R. N., Ruth, K. S., Tuke, M. A., Yaghootkar, H., Hu, Y., Teder-Laving, M., Hayward, C., Roenneberg, T., Wilson, J. F., Del Greco, F., Hicks, A. A., Shin, C., Yun, C. H., Lee, S. K., Metspalu, A., Byrne, E. M., Gehrman, P. R., ... Weedon, M. N. (2016). Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. *PLoS genetics*, 12(8), e1006125.
<https://doi.org/10.1371/journal.pgen.1006125>

Lane, J. M., Qian, J., Mignot, E., Redline, S., Scheer, F. A. J. L., & Saxena, R. (2023). Genetics of circadian rhythms and sleep in human health and disease. *Nature reviews. Genetics*, 24(1), 4–20.
<https://doi.org/10.1038/s41576-022-00519-z>

Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell*, 98(3), 365–376. [https://doi.org/10.1016/s0092-8674\(00\)81965-0](https://doi.org/10.1016/s0092-8674(00)81965-0)

Luo, G., Ambati, A., Lin, L., Bonvalet, M., Partinen, M., Ji, X., Maecker, H. T., & Mignot, E. J. (2018). Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. *Proceedings of the National Academy of Sciences of the United States of America*, 115(52), E12323–E12332.
<https://doi.org/10.1073/pnas.1818150116>

Luo, G., Zhang, J., Lin, L., & Mignot, E. J. (2022). Characterization of T cell receptors reactive to HCRTNH2, pHA273-287, and NP17-31 in control and narcolepsy patients. *Proceedings of the National Academy of Sciences of the United States of America*, 119(32), e2205797119.
<https://doi.org/10.1073/pnas.2205797119>

Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Vankova, J., Black, J., Harsh, J., Bassetti, C., Schrader, H., & Nishino, S. (2002). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Archives of neurology*, 59(10), 1553–1562. <https://doi.org/10.1001/archneur.59.10.1553>

Mitler, M. M., & Hajdukovic, R. (1991). Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. *Sleep*, 14(3), 218–220. <https://doi.org/10.1093/sleep/14.3.218>

Nirogi, R., Shinde, A., Goyal, V. K., Ravula, J., Benade, V., Jetta, S., Pandey, S. K., Subramanian, R., Chowdary Palacharla, V. R., Mohammed, A. R., Abraham, R., Dogiparti, D. K., Kalaikadhiban, I., Jayarajan, P., Jasti, V., & Bogan, R. K. (2024). Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. *Sleep medicine*, 124, 618–626. <https://doi.org/10.1016/j.sleep.2024.10.037>

Ollila, H. M., Sharon, E., Lin, L., Sinnott-Armstrong, N., Ambati, A., Yogeshwar, S. M., Hillary, R. P., Jolanki, O., Faraco, J., Einen, M., Luo, G., Zhang, J., Han, F., Yan, H., Dong, X. S., Li, J., Zhang, J., Hong, S. C., Kim, T. W., Dauvilliers, Y., ... Mignot, E. J. (2023). Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy. *Nature communications*, 14(1), 2709. <https://doi.org/10.1038/s41467-023-36120-z>

Partinen, M., Saarenpää-Heikkilä, O., Ilveskoski, I., Hublin, C., Linna, M., Olsén, P., Nokelainen, P., Alén, R., Wallden, T., Espo, M., Rusanen, H., Olme, J., Sätälä, H., Arikka, H., Kaipainen, P., Julkunen, I., & Kirjavainen, T. (2012). Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. *PloS one*, 7(3), e33723. <https://doi.org/10.1371/journal.pone.0033723>

Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y., Nevsimalova, S., Aldrich, M., Reynolds, D., Albin, R., Li, R., Hungs, M., Pedrazzoli, M., Padigaru, M., Kucherlapati, M., Fan, J., Maki, R., Lammers, G. J., Bouras, C., Kucherlapati, R., ... Mignot, E. (2000). A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nature medicine*, 6(9), 991–997. <https://doi.org/10.1038/79690>

Roth, T., Morse, A. M., Bogan, R., Roy, A., Gudeman, J., & Dauvilliers, Y. (2024). Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial. *Clinical therapeutics*, 46(10), 791–798. <https://doi.org/10.1016/j.clinthera.2024.07.010>

- Roy, A., Stern, T., Harsh, J., Hudson, J. D., Ajayi, A. O., Corser, B. C., Mignot, E., Santamaria, A., Morse, A. M., Abaluck, B., Ibrahim, S., Schweitzer, P. K., Lancaster, K., Dubow, J., & Gudeman, J. (2024). RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. *Sleep medicine: X*, 8, 100122. <https://doi.org/10.1016/j.sleepx.2024.100122>
- Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., ... Yanagisawa, M. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell*, 92(4), 573–585. [https://doi.org/10.1016/s0092-8674\(00\)80949-6](https://doi.org/10.1016/s0092-8674(00)80949-6)
- Scammell, T. E., Nishino, S., Mignot, E., & Saper, C. B. (2001). Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. *Neurology*, 56(12), 1751–1753. <https://doi.org/10.1212/wnl.56.12.1751>
- Stephansen, J. B., Olesen, A. N., Olsen, M., Ambati, A., Leary, E. B., Moore, H. E., Carrillo, O., Lin, L., Han, F., Yan, H., Sun, Y. L., Dauvilliers, Y., Scholz, S., Barateau, L., Hogg, B., Stefani, A., Hong, S. C., Kim, T. W., Pizza, F., Plazzi, G., ... Mignot, E. (2018). Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy. *Nature communications*, 9(1), 5229. <https://doi.org/10.1038/s41467-018-07229-3>
- Sun, Y., Tisdale, R. K., & Kilduff, T. S. (2021). Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. *Frontiers of neurology and neuroscience*, 45, 22–37. <https://doi.org/10.1159/000514963>
- Ten-Blanco, M., Flores, Á., Cristino, L., Pereda-Pérez, I., & Berrendero, F. (2023). Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies. *Frontiers in neuroendocrinology*, 69, 101066. <https://doi.org/10.1016/j.yfrne.2023.101066>
- Zhan, S., Ye, H., Li, N., Zhang, Y., Cheng, Y., Wang, Y., Hu, S., & Hou, Y. (2023). Comparative Efficacy and

Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis. *Nature and science of sleep*, 15, 217–230.

<https://doi.org/10.2147/NSS.S404113>